|
業務類別
|
Biotechnology |
|
業務概覽
|
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF. |
| 公司地址
| 1250 Page Mill Road, Palo Alto, CA, USA, 94304 |
| 電話號碼
| +1 650 281-0850 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.kodiak.com |
| 員工數量
| 124 |
| Dr. Victor Perlroth, M.D. |
Chief Executive Officer and Chairman of the Board |
美元 792.50K |
22/04/2026 |
| Mr. John A. Borgeson |
Executive Vice President, Chief Financial Officer, Secretary and Principal Accounting Officer |
美元 552.97K |
22/04/2026 |
|
|
| Mr. Robert A. Profusek, J.D. |
Lead Independent Director |
22/04/2026 |
| Dr. Taiyin Yang, PhD |
Independent Director |
22/04/2026 |
| Dr. Felix J. Baker, PhD |
Independent Director |
22/04/2026 |
| Dr. Richard S. Levy,M.D. |
Independent Director |
22/04/2026 |
| Mr. Charles A. Bancroft |
Independent Director |
22/04/2026 |
| Dr. Bassil I. Dahiyat, PhD. |
Independent Director |
22/04/2026 |
| Dr. Victor Perlroth, M.D. |
Chief Executive Officer and Chairman of the Board |
22/04/2026 |
|
|
|
|
